South Korean biotechnology firm Pangen has secured a government contract to develop a therapeutic antibody for Severe Fever with Thrombocytopenia Syndrome (SFTS), a tick-borne viral disease with a high case fatality rate. The project, commissioned by the Korea National Institute of Health (KNIH) under the Korea Disease Control and Prevention Agency (KDCA), aims to establish and validate a non-clinical production system for the treatment. The contract is valued at 2.75 billion KRW and spans three years, concluding on December 31, 2028.
What is SFTS and why is a treatment necessary?
SFTS is a tick-borne viral infection caused by the SFTS virus (SFTSV), a member of the Bandavirus genus. According to the Korea Disease Control and Prevention Agency (KDCA), the disease is characterized by fever, thrombocytopenia, and leukopenia, often leading to multi-organ failure. The mortality rate for SFTS in South Korea remains significant, fluctuating between 10% and 20% annually depending on clinical management. Currently, there are no approved vaccines or specific antiviral treatments for the disease. Medical professionals primarily rely on supportive care, such as fluid resuscitation and symptom management, as existing broad-spectrum antivirals have shown limited efficacy in clinical settings.
How does the proposed antibody therapy work?
Pangen’s research focuses on the development of a neutralizing antibody designed to target the SFTS virus directly. By binding to the virus’s surface proteins, the antibody prevents the pathogen from infiltrating host cells. This mechanism also stimulates the patient’s immune system to identify and clear the viral particles. In preclinical trials, the company reports that the antibody demonstrated high survival rates in animal models exposed to lethal doses of the virus. While these results are promising, the KNIH contract requires further validation of the production process to ensure the therapy meets the rigorous safety and quality standards required for human clinical trials.
Financial and strategic impact for Pangen
The 2.75 billion KRW contract represents approximately 20.46% of Pangen’s total revenue reported for the 2025 fiscal year. For the company, this agreement serves as both a revenue stream and a strategic move to diversify its portfolio beyond its established biosimilar and Contract Development and Manufacturing Organization (CDMO) operations. Pangen CEO Yoon Jae-seung stated that the successful commercialization of this antibody could provide a vital tool for reducing fatality rates and preventing secondary transmission in clinical environments. The company intends to integrate this research into its broader infectious disease pipeline.
Current status of SFTS research
Globally, research into SFTS therapeutics is active, though it remains in the developmental stage. The strategy of using neutralizing antibodies is a common approach in modern virology, similar to treatments developed for other zoonotic viruses. Unlike traditional small-molecule drugs, monoclonal antibodies offer high specificity, potentially reducing side effects. However, the success of this project depends on the transition from laboratory-scale production to the “advanced non-clinical production system” mandated by the KNIH. This transition is a critical hurdle for any biotech firm, as it requires scaling up manufacturing processes while maintaining strict adherence to Good Manufacturing Practice (GMP) guidelines.
Key Facts Summary
- Target Disease: Severe Fever with Thrombocytopenia Syndrome (SFTS).
- Project Scope: Development of a neutralizing antibody and non-clinical production systems.
- Contract Value: 2.75 billion KRW.
- Timeline: Three-year duration ending December 31, 2028.
- Clinical Need: Addressing the current lack of specific antiviral treatments for a disease with a mortality rate of up to 20%.